Table 2. Summary of meta-analysis and systematic reviews on ALPPS.
| Author, Year | Type | # included patients | FLR increase (%) | Rates of complete ALPPS (%) | Morbidity (%) (> Clavien-Dindo 3a) | Mortality (%) | Remarks |
|---|---|---|---|---|---|---|---|
| Schnitzbauer et al., 2012 (65) | Retrospective cohort study | 25 | 74 (RH) | 100 | 44 | 12 (during index admission) | |
| Knoefel et al., 2013 (69) | Prospective cohort study | 7 | 63 (RH) | 100 | 71.4 | 14.3 (7 days) | |
| Nadalin et al., 2014 (70) | Retrospective cohort study | 15 | 87.2 (RH) | 100 | 66.7 | 28.7 (within 36 days) | |
| Schadde et al., 2014 (66) | Prospective cohort study | 202 | 80 (RH) | 98 | 40 | 9 (90 days) | Age <60, CRLM group with better survival |
| Sandstrom et al., 2018 (67) | Randomized controlled trial | 48 | 68 (RH) | 92 | 43 | 9 (90 days) |
ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; FLR, future liver remnant; RH, relative hypertrophy; CRLM, colorectal liver metastasis.